Pain Management Market Share

Global Pain Management Market Overview

Pain Management Market Size was valued at USD 71.38 Billion in 2023. The Global Pain Management industry is projected to grow from USD 75.15 Billion in 2024 to USD 114.33 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.39% during the forecast period (2024 - 2032). 

You must know that Pain is considered a social, clinical, and financial weight in networks throughout the planet, as constant torment is related to different ailments. The expanding commonness of torment or Pain pushes the interest for better determination and medicines. Prominently, the Market size is relied upon to grow soon because of expanding innovative headways. The expanding events of constant pain conditions are ceaselessly propelling advertisers to think of more innovatively progressed items.

Pain is an uncomfortable sensory and emotional experience that follows tissue injury or illness. Additionally, several illnesses, including cancer, multiple sclerosis, stomach ulcers, chronic arthritis, osteoarthritis, fibromyalgia, and chronic gout, can be uncomfortable. The market for pain management has grown tremendously due to the long-standing practice of employing painkiller drugs as the first line of treatment. However, in recent years, device-based pain management therapy has grown due to an increasing dependence on their long-term use and a better awareness of their negative effects. The most typical type of pain is post-operative discomfort. There is a high demand for pain relief medications and equipment since monitoring and treating side effects is expensive. Acute pain can last for a short while, but chronic pain can last very long. Acute discomfort might be slight and linger for a split second, several weeks, or even months. Age-related bone and joint disorders, nerve damage, or injuries are the main causes of chronic pain. 

There are now some non-opioid medications in the initial and final stages of development. The regulatory agencies in many nations are switching to alternative methods, hastening the approval of those products for the market. As the world's population ages, the market is anticipated to rise. Chronic pain is quite common among the elderly and is considered a separate risk factor for mortality. Additionally, the prevalence of chronic diseases like diabetic neuropathy, cancer, and osteoarthritis is rising, fueling market expansion. The market for painkillers is also predicted to expand due to a rise in surgical procedures and healthcare expenditures. However, drug abuse, the patent expiration of prescription medications, and the high cost of drugs prevent the market from growing.

News: A new clinical practice guideline created by the University of Pittsburgh School of Dental Medicine, the American Dental Association Science & Research Institute (ADASRI), and the Center for Integrative Global Oral Health at the University of Pennsylvania School of Dental Medicine recommends ibuprofen or acetaminophen as the first-line treatments for managing short-term dental pain in children under the age of 12. The American Dental Association has approved the recommendation.

In July 2024, Codman and Shurtleff have introduced a novel smart neuromodulation device that aims to improve pain management accuracy by employing real-time feedback and adaptive algorithms.

In June 2024, Roche launched an AI-powered pain management platform aiming at enhancing individualized treatment plans by evaluating patient data and predicting pain outcomes in order to adjust treatments more efficiently.

The Senza, a new type of spinal cord stimulator for chronic pain developed by the FDA in February 2023. The wireless Senza is implanted beneath the skin.Prialt was then approved by the FDA in January 2023 as a first-line drug for people suffering from continuous pain that does not result from opioid abuse. Prialt is an injectable long-acting drug that acts by blocking pain signals in your brain.

On 2023 February, FDA authorized a new type of chronic pain spinal cord stimulator known as Senza. Senza is implanted under the skin and it is wireless.

The first non-opioid drug for chronic pain called Prialt was approved by the FDA in January 2023. It is a long-acting injectable agent that blocks pain signals to the brain.

In October 2022, Parker Laboratories Inc., developers, manufacturers and sellers of analgesics creams, ultrasound and electromedical contact media, and institutional cleaners and disinfectants are expanding their analgesics line. The company has added Helix CBD Therapy Cream, CBD Clinical Cream as well as Tri-Active Therapy Cream to its line of products named HelixTM.

This acquisition was made on February 1st, 2022, when Boston Scientific Corporation acquired Baylis Medical Company Inc, thus extending its electrophysiology product portfolio along with structural heart portfolios like VersaCross Transseptal and radiofrequency NRG Platforms and dilators used for left heart access.

Pain Management Market Trends

• Modern Pain Management Techniques to boost the market growth

The market participants have been spending consistently on the creation of cutting-edge solutions for the treatment of chronic pain. One of the most significant developments in the market for treating chronic pain is innovation in wearable technologies. For instance, in September 2020, NeuroMetrix Inc. introduced its wearable technology for the management of chronic pain. The product is called Quell, a wearable transcutaneous electrical nerve stimulation (TENS) device for people with knee, foot, and leg pain. Through a mobile application on iPhone and Android smartphones, users may discreetly customize and control their therapy.

Pain Management Market Segment Insights

Pain Management Type Insights

The market segmentation, based on type, includes Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticonvulsants, Sedatives, Narcotics, Antimigraine specialists, Antidepressants, and Others. The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) segment held the majority share in 2021, This is because these drugs are effective in treating a wide variety of conditions, including pain, inflammation, and fever. As a result, they are the first choice of treatment for many people this will increase Pain Management market revenue.

Pain Management Indication Insights

Based on Indication, the market segmentation includes Delegated neuropathic torment, Disease torment, Facial agony and headache, Musculoskeletal torment, Fibromyalgia, Persistent back torment, Joint torment, Headache, and Post-usable torment. The Musculoskeletal torment segment is projected to be the faster-growing segment during the forecast period, 2024-2032. This growth is attributable to the expanding demand for prescription medications to manage diverse disorders, which helps increase sales these all factors for Pain Management positively impact the market growth.

Pain Management Mode of purchase Insights

Based on the Mode of purchase, the market segmentation includes Over counter, Solution-based. The over-the-counter (OTC) segment dominated the pain management market growth in 2021. This is due to the availability of OTC products and the fact that they are typically cheaper than prescription medications. OTC products are also generally considered to be safer than prescription drugs.

Pain Management End-User Insights

Based on End-User, the market segmentation includes Emergency clinics and facilities, Drug organizations, Clinical gadget organizations, Examination, Educational establishments, and Others. The Emergency clinics and facilities segment dominated the market in 2021. This is attributed to the increasing number of emergency visits for pain management and the rising number of pain management clinics and facilities, which helps increase sales for Pain Management and positively impact the market growth.

Figure 2: Pain Management Market, by End-User, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

News: On 21 of 24 areas of pain treatment and assessment for patients, a Delphi panel of 10 people reached an agreement. All the panelists had experience treating Fabry disease patients in the UK. Currently, there is no definite agreement on assessing and treating pain in these patients within clinical practice in the United Kingdom. The researchers claimed the findings can assist direct the development of therapeutic guidelines.

Pain Management Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The market is dominated by North America, with the United States accounting for the bulk of its revenue. In North America, the market is anticipated to increase as a result of factors such as the aging population's rising desire for long-term pain management and advancements in the field of pain management. Additionally, according to the American Society of Regional Anesthesia and Pain Medicine's (ASRA) recommendations, long-term opioid therapy and the use of steroids during interventional pain procedures may cause immune suppression, which is crucial because it reduces the body's ability to fight off a variety of viral infections.

Figure 3: PAIN MANAGEMENT MARKET SHARE BY REGION 2023 (%)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe region accounts for the second-largest market share. This is because the continent has a large and aging population, as well as a high prevalence of chronic pain conditions. In addition, there is a growing awareness of the importance of pain management and the need for effective treatments.

The APAC market is anticipated to develop at the quickest rate throughout the projected period, primarily due to the region's expanding elderly population, expanding per capita income, and improving healthcare infrastructure. The number of elderly people in Asia is anticipated to double, according to the United Nations (UN) Department of Economic and Social Affairs study on the aging of the world population. The prevalence of chronic pain conditions among the elderly, such as arthritis, neuropathic illnesses, and back pain, contributes to the demand for medications and medical devices to manage chronic pain.

Pain Management Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Pain Management industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to cut operating costs is one of the main business tactics manufacturers use in the Pain Management industry to benefit customers and expand the market sector. The market has recently given medicine some of the most important advantages. Major hair care product market players, including Abbott Laboratories, Stryker Corporation, Codman And Shurtleff Inc, F. Hoffmann-La Roche Ltd, and others, are attempting to increase market demand by funding R&D initiatives.

Abbott Laboratories is a company founded in 1888 that discovers, develops, manufactures, and sells a wide range of healthcare products. It operates in the following areas: Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices are well-established. The Established Pharmaceutical Goods section includes overseas sales of branded generic pharmaceutical products. The Nutritional Items business sells nutritional products to adults and children. Diagnostic Products sells diagnostic systems and tests to blood banks, hospitals, commercial laboratories, and alternate-care testing facilities. Electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, diabetes care products for persons with diabetes, and neuromodulation devices for the management of chronic pain and mobility disorders are all part of the Medical Devices section.

Stryker, founded in 1941, is a medical technology company that operates in three business segments: orthopedics, medical and surgical, and neurotechnology and spine. Orthopedic implants are utilized in hip and knee joint replacements, as well as trauma and extremity procedures. Medical and Surgical equipment and navigation, endoscopic and communications systems, patient management and emergency medical equipment, and reprocessed and remanufactured medical devices are all available within the Medical and Surgical segment. Neurotechnology and Spine provide neurosurgery and neurovascular products for minimally invasive endovascular treatments.

Key Companies in the Pain Management market include

• 
  

  Abbott Laboratories

  
  


• 
  

  Stryker Corporation

  
  


• 
  

  Codman And Shurtleff, Inc

  
  


• 
  

  F. Hoffmann-La Roche Ltd

  
  


• 
  

  Abbvie

  
  


• 
  

  Allergan

  
  


• 
  

  AstraZeneca plc

  
  


• 
  

  Bayer AG

  
  


• 
  

  DJO LLC

  
  


• 
  

  Eli Lilly & Company

  
  


• 
  

  Endo Health Solution

  
  

Pain Management Industry Developments

January 2021: Abbott Laboratories announced the launch of NeuroSphere myPath, a digital health application meant to measure and report on patient-perceived pain reduction and general well-being linked with spinal cord stimulation (SCS) or DRG therapy.

November 2020: Abbott Laboratories will release the IonicRF generator, a radiofrequency ablation device that utilizes heat to target specific neurons and prevent pain signals from reaching the brain.

Pain Management Market Segmentation

Pain Management Type Outlook

• 
  

  Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

  
  


• 
  

  Anticonvulsants

  
  


• 
  

  Sedatives

  
  


• 
  

  Narcotics

  
  


• 
  

  Antimigraine specialists

  
  


• 
  

  Antidepressants

  
  


• 
  

  Others

  
  

Pain Management Indication Outlook

• 
  

  Delegated neuropathic torment

  
  


• 
  

  Disease torment

  
  


• 
  

  Facial agony and headache

  
  


• 
  

  Musculoskeletal torment

  
  


• 
  

  Fibromyalgia

  
  


• 
  

  Persistent back torment

  
  


• 
  

  Joint torment

  
  


• 
  

  Headache

  
  


• 
  

  Post-usable torment

  
  

Pain Management Mode of purchase Outlook

• 
  

  Over the counter

  
  


• 
  

  Solution-based

  
  

Pain Management End-User Outlook

• 
  

  Emergency clinics and facilities

  
  


• 
  

  Drug organizations

  
  


• 
  

  Clinical gadget organizations

  
  


• 
  

  Examination

  
  


• 
  

  Educational establishments

  
  


• 
  

  Others

  
  

Pain Management Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America